The reiteration of a Buy rating and maintenance of a $6 price target by a reputable analyst firm like HC Wainwright & Co. suggests a strong belief in Iterum Therapeutics' potential for growth. This positive outlook is likely to influence investor sentiment and could lead to an increase in stock price in the short term, especially if the market reacts favorably to analyst ratings.